Generics Infringe On Branded Stock Growth As Investors Eye Mergers, Part D
Executive Summary
Generic drug consolidation and the pending implementation of Medicare Part D in January, with its cost pressures likely to benefit unbranded drugs, appear to be swaying investor confidence in favor of generic drug makers
You may also be interested in...
Actavis Buying Spree Includes Alpharma In Race For Generic Top Three
Actavis plans to acquire Alpharma's generic drug business for $810 mil., marking the Reykjavik, Iceland based company's seventh acquisition of the year
Actavis Buying Spree Includes Alpharma In Race For Generic Top Three
Actavis plans to acquire Alpharma's generic drug business for $810 mil., marking the Reykjavik, Iceland based company's seventh acquisition of the year
Generic Industry Faces Consolidation As Indian Firms Look To Enter U.S.
The generic industry will face continued pricing pressure as Indian firms move into the U.S. market, ABN-AMRO Healthcare Banking Director Tommy Erdei told the Generic Pharmaceutical Association Sept. 19